$11.59
1.45% yesterday
Nasdaq, May 20, 09:46 pm CET
ISIN
US05463X1063
Symbol
AXGN

AxoGen, Inc. Stock price

$11.57
-3.61 23.78% 1M
-1.33 10.31% 6M
-4.91 29.79% YTD
+5.37 86.61% 1Y
+1.57 15.70% 3Y
+3.35 40.75% 5Y
+8.51 278.10% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.19 1.62%
ISIN
US05463X1063
Symbol
AXGN
Sector

Key metrics

Market capitalization $526.94m
Enterprise Value $567.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 476.73
EV/Sales (TTM) EV/Sales 2.92
P/S ratio (TTM) P/S ratio 2.71
P/B ratio (TTM) P/B ratio 5.00
Revenue growth (TTM) Revenue growth 18.81%
Revenue (TTM) Revenue $194.52m
EBIT (operating result TTM) EBIT $-478.00k
Free Cash Flow (TTM) Free Cash Flow $1.19m
Cash position $28.07m
EPS (TTM) EPS $-0.16
P/E forward negative
P/S forward 2.43
EV/Sales forward 2.62
Short interest 3.77%
Show more

Is AxoGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

AxoGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a AxoGen, Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a AxoGen, Inc. forecast:

Buy
100%

Financial data from AxoGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
195 195
19% 19%
100%
- Direct Costs 50 50
51% 51%
26%
144 144
11% 11%
74%
- Selling and Administrative Expenses 110 110
3% 3%
57%
- Research and Development Expense 26 26
9% 9%
14%
7.34 7.34
159% 159%
4%
- Depreciation and Amortization 7.82 7.82
26% 26%
4%
EBIT (Operating Income) EBIT -0.48 -0.48
97% 97%
0%
Net Profit -7.16 -7.16
66% 66%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about AxoGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AxoGen, Inc. Stock News

Neutral
Seeking Alpha
11 days ago
Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
13 days ago
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2025.
Neutral
GlobeNewsWire
27 days ago
ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report 2025 first quarter financial results on Thursday, May 8, 2025, before the market opens. Axogen management will host an investment-community conference call and webcast...
More AxoGen, Inc. News

Company Profile

AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Head office United States
CEO Michael Dale
Employees 452
Founded 1977
Website www.axogeninc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today